{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 53,
  "pageCount": 53,
  "prevPage": 52,
  "nextPage": null,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "This appears to be a page from a formal government or committee report, likely an appendix or disclosure section.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/53",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-53",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The Committee remains committed to uncovering the full scope of McKinsey's consulting in furtherance of abusive practices and conflicts of interest across the federal government.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49e-926fe2ba1a90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.024,
        "x": 0.488,
        "y": 0.938
      },
      "kind": "other",
      "text": "53",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75d052f0-c90d-467c-ae63-f7dd6d612692",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.033,
        "w": 0.766,
        "x": 0.117,
        "y": 0.117
      },
      "kind": "paragraph",
      "text": "government health care practice incorporating feedback from consultants serving private sector opioid clients and altering work product in ways that appeared to serve those clients' interests.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f4de326-43b5-4fa6-90d7-3bbf8f572b0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.067,
        "w": 0.766,
        "x": 0.117,
        "y": 0.317
      },
      "kind": "paragraph",
      "text": "McKinsey's conduct raises significant questions about the lack of regulation over consulting companies that advise both the federal government and private sector clients. The Committee remains committed to uncovering the full scope of McKinsey's consulting in furtherance of abusive practices and conflicts of interest across the federal government.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa51458-761b-404b-b8bb-a91a764958fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.766,
        "x": 0.117,
        "y": 0.167
      },
      "kind": "paragraph",
      "text": "This interim report addresses McKinsey's conflicts with respect to only one type of client: opioid manufacturers. Over five months ago, the Committee requested information on McKinsey's consulting for other pharmaceutical companies, drug distributors, and drug retailers—as well as key documents on McKinsey's risk management practices. McKinsey has failed to provide most of the key documents that would allow the Committee to fully assess how its consulting practices and conflicts of interest have affected the health and safety of the American people.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78b97d2f-fdf9-4711-80b8-6aac89792fb4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 53,
      "from": 29,
      "beatId": "1170eac2-9202-4b41-a53c-edbd934ded10",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document concludes with implications of McKinsey's actions and potential next steps for regulatory action.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}